

# **Improving Anti-Breast Cancer Vaccines by Overcoming Tumour Induced Immunosuppressive Factors**

Kimberley Ann Stannard  
Bsc (applied biology)/ BHSc (Hons)

School of Medical Science  
Griffith Health  
Griffith University

Submitted in fulfilment of the requirements of the degree of  
Doctor of Philosophy

October 2011

## **Abstract**

Cancers are a rapidly increasing source of morbidity and mortality for Australians. In 2005, there were over 100,000 new cases of cancer diagnosed and this number is projected to grow by over 3,000 extra cases per year in 2006–2010. Although traditional therapies such as surgery, chemotherapy and radiation therapy may extend the life of many patients, the treatments are associated with severe toxicities and are rarely curative for disseminated cancers. The idea of harnessing the immune system for the treatment of cancers represents an attractive treatment modality which should effectively complement current treatment methods. Immunotherapies, including cancer vaccines, are designed to re-train the immune system to recognise and destroy cancer cells and tip the balance from tumour acceptance toward active tumour immunity. However, many cancer vaccine approaches have failed to live up to their potential. Cancers employ many immunosuppressive factors which contribute to nullifying anti-tumour immune responses during vaccination therapy. These immunosuppressive factors include galectin-1, regulatory T-cells (Tregs) and inhibitory molecules such as CTLA-4, which are potential targets in the enhancement of immunotherapeutic strategies. This thesis aimed to investigate the role of these tumour derived immunosuppressive factors and to enhance the immune response towards an allogeneic whole cell breast cancer vaccine using a murine model of breast cancer.

Chapter 3 outlines the development of a highly immunogenic murine breast cancer cell line used in vaccination protocols throughout this study. Moderate increases in survival and slower tumour growth rates were observed both in prophylactic and treatment settings. The results demonstrated that factors involved in tumourigenesis may overwhelm the anti-cancer immune responses generated by vaccination. In Chapter 4, the role of galectin-1 was studied for its effects on T-cell subpopulations and the induction of CTL responses against breast cancer cells. Certain disaccharides that block galectin-1 from interacting with other

carbohydrates and glycoproteins on cell surfaces were examined for their ability to enhance the potency of the cancer vaccine. These studies demonstrated that small carbohydrate molecules can be administered *in vivo* to inhibit the immunosuppressive activity of galectins and restore the immune environment, significantly inhibiting the growth of breast cancers to improve survival outcomes.

Chapter 5 investigated the role of Tregs and the CTLA-4 negative co-stimulatory molecule in inhibiting immune responses targeted toward murine breast tumours. Specifically, the administration of monoclonal anti-bodies (MAbs) which target Tregs was investigated. The results presented in this chapter clearly demonstrated that removing the immunosuppressive activity of Tregs by targeting their CTLA-4 surface receptor function is clearly preferable to broadly targeting Tregs through CD25 expression. This is demonstrated by enhanced the anti-tumour immune activity and increased survival in mice receiving anti-CTLA-4 MAb therapy. Furthermore, this chapter indicates that combining anti-cancer vaccination with CTLA-4 blockade induces increased CD8<sup>+</sup> TIL, thereby inhibiting tumour growth and increasing survival above that of either approach used alone.

Chapter 6 investigated the effect of triple combination immunotherapy which combined the agents trialled in previous chapters to form an ultimate cocktail immunotherapy. Taking into account inter-experimental variability and control populations which were consistently ran in parallel, results in this chapter demonstrated that combination immunotherapy consisting of a whole cell cancer vaccine, an anti-CTLA-4 mAb and an anti-galectin disaccharide, provides a superior approach for enhancing anti-tumour immune responses than the use of stand-alone therapies. The role of galectin-1 and CTLA-4 in the appropriation of the Treg phenotype was also investigated. It was shown that both galectin-1 and CTLA-4 expression on naive CD4<sup>+</sup>CD25<sup>-</sup> T-cell contributes significantly to the conversion of cells to the CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Treg phenotype and that inhibiting these

molecules could significantly reduce this conversion with implications for altering the intratumoural ratio of CD8<sup>+</sup> effector T-cells to the immunosuppressive CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Tregs.

The results of this thesis highlight the fact that in order to improve current cancer therapies, including immunotherapies, a combinatorial approach must be used to combat as many evasion strategies as possible to tilt the balance back in favour of tumour elimination. This study demonstrates that a triple combination of a cancer vaccine with galectin-1 inhibition and the removal of negative co-stimulatory signals through CTLA-4 blockade can significantly improve outcomes for tumour challenged animals over any agent used alone, reinforcing the necessity for combination therapy to be applied in the current clinical setting.

## **Statement of Originality**

This work has not previously been submitted for a degree or diploma in any university. To the best of my knowledge and belief, the thesis contains no material previously published or written by another person except where due reference is made in the thesis itself.

(Signed)\_\_\_\_\_

## Acknowledgement of published papers included in this thesis

Section 9.1 of the Griffith University Code for the Responsible Conduct of Research (“Criteria for Authorship”), in accordance with Section 5 of the Australian Code for the Responsible Conduct of Research, states:

To be named as an author, a researcher must have made a substantial scholarly contribution to the creative or scholarly work that constitutes the research output, and be able to take public responsibility for at least that part of the work they contributed. Attribution of authorship depends to some extent on the discipline and publisher policies, but in all cases, authorship must be based on substantial contributions in a combination of one or more of:

- conception and design of the research project
- analysis and interpretation of research data
- drafting or making significant parts of the creative or scholarly work or critically revising it so as to contribute significantly to the final output.

Section 9.3 of the Griffith University Code (“Responsibilities of Researchers”), in accordance with Section 5 of the Australian Code, states:

Researchers are expected to:

- Offer authorship to all people, including research trainees, who meet the criteria for authorship listed above, but only those people.
- accept or decline offers of authorship promptly in writing.
- Include in the list of authors only those who have accepted authorship
- Appoint one author to be the executive author to record authorship and manage correspondence about the work with the publisher and other interested parties.
- Acknowledge all those who have contributed to the research, facilities or materials but who do not qualify as authors, such as research assistants, technical staff, and advisors on cultural or community knowledge. Obtain written consent to name individuals.

Included in this thesis is 1 published paper in *Chapter 4* which is co-authored with other researchers. My contribution to the co-authored paper is outlined at the front of the relevant chapter. The bibliographic details for this paper are:

Chapter 4: Stannard, K. A., P. M. Collins, et al. (2010). "Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model." Cancer Lett **299**(2): 95-110.

Appropriate acknowledgements of those who contributed to the research but did not qualify as authors are included in the published paper.

(Signed) \_\_\_\_\_

Name of Student

(Countersigned) \_\_\_\_\_

Supervisor: Name of Supervisor

## Table of Contents

<b>Abstract.....</b>	<b>2</b>
<b>List of figures .....</b>	<b>13</b>
<b>List of Tables.....</b>	<b>17</b>
<b>Acknowledgements.....</b>	<b>23</b>
<b>Chapter 1: .....</b>	<b>25</b>
<b>Literature Review.....</b>	<b>25</b>
<b>1.1 Introduction: Cancer .....</b>	<b>26</b>
<b>1.2 Breast cancer and murine models of the disease .....</b>	<b>27</b>
<b>1.3 Tumourigenesis -Four stages of tumour pathogenesis: Hyperplasia, Dysplasia, In situ cancer, Invasive cancer. ....</b>	<b>30</b>
<b>1.4 Immunosurveillance and immunoediting .....</b>	<b>34</b>
<b>1.5 Tumour Immune Evasion.....</b>	<b>38</b>
1.5.1 Evasion from antigenic recognition.....	39
1.5.2. Tumour-induced immunosuppression .....	42
<b>1.5.2.1 Interference with apoptotic signaling pathways .....</b>	<b>45</b>
1.5.2.2 Down Regulation of the Major Histocompatibility Complex (MHC's)....	48
<b>1.5.2.3 Lack of co-stimulation .....</b>	<b>49</b>
<b>1.5.3 Cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression.....</b>	<b>51</b>
<b>1.6 Regulatory T-cells (Tregs) and cancer .....</b>	<b>55</b>
1.6.1 Overview .....	55
1.6.2 Treg markers and classification.....	56
1.6.3 Tregs and cancer .....	58
1.6.4 Immunotherapeutic strategies targeting Tregs.....	59
<b>1.7 The Galectins and their role in cancer and immunity .....</b>	<b>62</b>
1.7.1 Overview of galectin production and function.....	62
1.7.2 Galectins and the immune response .....	64
1.7.5 Galectin-1 inhibition.....	76
<b>1.8 Cancer Immunotherapy.....</b>	<b>80</b>
1.8.1 Nonspecific immunotherapy.....	80
1.8.2 Antigen specific immunotherapies .....	81
<b>1.9 Cancer vaccines .....</b>	<b>83</b>
<b>1.10 Aims .....</b>	<b>87</b>

<b>Chapter 2: Materials and Methods.....</b>	<b>91</b>
<b>2.1 Materials .....</b>	<b>92</b>
2.1.1 Mice .....	92
2.1.2 Reagents and equipment used for flow cytometry and cell sorting. ....	95
2.1.3 Reagents and equipment used for molecular biological techniques such as PCR, DNA amplification and extraction and DNA transfection .....	96
2.1.4 Reagents and equipment used for immunohistochemical analysis of tumour samples .....	99
<b>2.2 Methods .....</b>	<b>101</b>
2.2.1 Cell lines and culture conditions.....	101
2.2.1.1 Cryopreservation and resuscitation of cells.....	102
2.2.1.3 Cell viability assay by trypan blue dye exclusion .....	102
2.2.1.4 In vivo tumour cell implantation .....	103
2.2.1.5 Preparation and culture of lymphocytes and splenocytes from whole blood, lymph node, spleen and tumour tissue.....	104
2.2.2 PCR and Gel Electrophoresis .....	105
2.2.2.1 DNA isolation.....	105
2.2.2.2 PCR.....	106
2.2.2.3 Gel Electrophoresis .....	106
2.2.3 Preparation of B7.1 DNA for Cell Transfection .....	107
2.2.3.1 Bacterial Transformation .....	107
2.2.3.2 Plasmid DNA mini-preparations (Alkaline lysis method) .....	107
2.2.3.3 Plasmid DNA maxi-preparations (alkaline lysis method).....	108
2.2.3.4 Caesium chloride density gradient centrifugation.....	109
2.2.4 Cell Transfection .....	110
2.2.5 MHC class I induction .....	111
2.2.5.1 MHC class I receptor up-regulation by IFNs. ....	111
2.2.6 Flow Cytometry .....	113
2.2.6.1 Fluorescent immunostaining for surface located antigens.....	113
2.2.6.2 Intra-cellular immunofluorescence staining .....	114
2.2.6.3 B7 Expression and MoFlo cell sorting.....	114
2.2.6.4 Flow Cytometric Analysis of Apoptosis.....	115
2.2.6.5 Flow cytometric analysis of CD8/CD4/CD25/FoxP3 T-cell Populations.....	116
2.2.7 Vaccine Preparation and Vaccination Protocol.....	117
2.2.8 Preparation of Splenocytes for mixed lymphocyte culture MLC and CTL Assays .....	117
2.2.9 In Vitro Addition of Galectin-binding disaccharides and recombinant human (rh) Gal-1 protein.....	119
2.2.10 Treatment of MOLT-4 cells with rhGal-1 .....	120



2.2.11 Treg induction assay.....	120
2.2.12 Study protocols used in testing immunotherapies on animals models of breast cancer .....	121
2.2.12.1 <i>In vivo anti-breast cancer vaccination study</i> .....	121
2.2.12.2 <i>Determining the effect of blocking Gal-1 with TDG in combination with vaccine therapy</i> .....	122
2.2.12.3 <i>Determining the effect of Vaccine therapy combined with Treg inhibitory antibodies</i> .....	122
2.2.13 Development of a CTL assay .....	124
2.2.13.1 DELFIA Cytotoxicity Assay .....	124
2.2.13.1.1 Preparation of target cells for cytotoxicity assay .....	124
2.2.13.1.2 Preparation of Effector lymphocytes.....	125
2.2.13.1.3 DELFIA Cytotoxicity assay protocol .....	125
2.2.13.2 Europium Diethylenetriaminopentaacetate (EuDPTA) cytotoxicity assay	127
2.2.13.2.1 Preparation of Target cancer cells for cytotoxicity assay .....	127
2.2.13.2.2 Preparation of Effector lymphocytes.....	127
2.2.13.2.3 EuDPTA Cytotoxicity assay protocol.....	128
2.2.13.3 Development of a CTL assay based on luciferase enzyme activity being released from lysed Target cells.....	129
2.2.13.3.1 Preparation of Targets .....	129
2.2.13.3.2 Preparation of effectors.....	129
2.2.13.3.3 Luciferase cytotoxicity assay protocol .....	129
2.2.13.4 SytoxGreen® Cytotoxicity assay .....	130
2.2.13.4.1 Preparation of effectors.....	130
2.2.13.4.1 Preparation of Target cells .....	130
2.2.13.4.2 Definition of lytic units.....	131
2.2.14 Immunohistochemical analysis of tumour samples .....	132
2.2.14.1 Antibodies, dyes and reagents. ....	132
2.2.14.2 Conjugation of antibodies to Alexa fluor® carboxylic acid, succinimidyl ester dyes.....	132
2.2.14.3 Calculating Degree of Labelling (DOL).....	133
2.2.14.4 Tissue sectioning and staining. ....	134
2.2.14.4.1 Tissue embedding.....	134
2.2.14.4.2 Tissue sectioning.....	134
2.2.14.4.3 Tissue staining.....	134
2.2.15 Statistical analysis.....	135

### **Chapter 3: Enhancing antigenicity of a breast cancer vaccine to increase CD8<sup>+</sup> CTL immune responsiveness in a transgenic mouse breast cancer model..... 137**

#### **3.1 Introduction..... 138**

##### **3.1.1 The HER-2/neu murine breast cancer model..... 138**

3.1.2 Role of the IFNs: increasing the ability of cancer cells to be recognised by immune killer cells.....	139
3.1.3 Combined effects of B7 expression and IFN treatment of tumour cells on the CTL response .....	141
<b>3.2 Results .....</b>	<b>143</b>
3.2.1 Comparison of mitomycin C treatment and irradiation in the preparation of cells used in vaccination or MLC.....	143
3.2.2 Optimisation of IFN $\gamma$ / $\beta$ treatment to enhance the MHC class I antigen presentation on cells for inclusion in a breast cancer vaccine.....	145
3.2.3 Production of transfected NeuTL cell lines expressing increased surface levels of B7-1 .....	149
3.2.4 Increased levels of MHC class I and B7-1 expression promote the survival of lymphocytes in mixed lymphocyte culture (MLC).....	153
3.2.5 Determining the extent of production of splenic derived lymphocytes post vaccination with IFN $\gamma$ 48/ $\beta$ 24 NeuTL B7-1 Hi cells .....	155
3.2.6 Preclinical trial of breast cancer vaccine in preventative and therapeutic settings .....	157
3.2.6.1 <i>Use of breast cancer vaccine to prevent or treat spontaneously developing breast tumours in the FVB/N c-neu transgenic mouse model.....</i>	157
3.2.6.2 <i>Use of a breast cancer vaccine to prevent or treat cancer in a transplantable tumour model. ....</i>	161
3.2.6.3 <i>Breast cancer vaccination reduces tumour progression and increases survival outcomes of tumour bearing mice. ....</i>	164
3.2.7 <i>Development of CTL assays for monitoring immune cell responses to vaccination. ....</i>	167
3.2.7.1 <i>The Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFLIA) Cytotoxicity Assay.....</i>	167
3.2.7.2 <i>Europium Diethylenetriaminopentaacetate (EuDPTA) cytotoxicity assay. ....</i>	168
3.2.7.3 <i>Bioluminescent cytotoxicity assay in Target Cells. ....</i>	169
3.2.7.3.1 <i>Development of the luminescent target cells .....</i>	169
3.2.7.3.2 <i>Improving bioluminescent target cell viability for CTL assays .....</i>	172
3.2.7.4 <i>Use of fluorescent dyes as indicators of target cell death in CTL assays.....</i>	177
<b>3.3 Discussion .....</b>	<b>182</b>
3.3.1 Vaccine development and optimisation.....	182
3.3.2 CTL assay development.....	186

<b>Chapter 4. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model .....</b>	<b>189</b>
<b>4.1 Introduction .....</b>	<b>191</b>

## **Chapter 5. Enhancing the potency of a breast cancer vaccine by combining therapy with antibodies inhibiting regulatory T-cell function..... 209**

<b>5.1 Introduction .....</b>	<b>210</b>
<b>5.2 Results .....</b>	<b>212</b>
5.2.1 Size of breast cancers shows a direct correlation with levels of CD25 <sup>+</sup> T-lymphocytes isolated from the tumours.....	212
5.2.2 Levels of Treg populations present in tumour bearing mice with either spontaneous FVBN-MMTV rat C-neu or Wild Type NeuTL cell induced tumours.....	214
5.2.3 Treatment with Treg inhibitory MAb does not affect the level of CD8 <sup>+</sup> T-cells, but significantly reduces Treg populations.....	217
5.2.4 Single treatment with anti-CD25 MAb significantly reduces CD25 <sup>+</sup> T-cell levels for prolonged time periods whereas anti-CTLA-4 MAb treatment does not significantly affect this population .....	219
5.2.5. Combined therapy by vaccination with a whole syngeneic breast cancer vaccine together with anti-Treg MAb increases levels of CD8 <sup>+</sup> cells in the spleen.....	221
5.2.6 Determining the optimal dose of anti-CD25 MAb to inhibit Treg cells for use in in vivo cancer vaccination trials. ....	224
5.2.7 Combination therapy with a breast cancer vaccine together with anti-CD25 MAb promotes CD8 <sup>+</sup> TILs and reduces level of Tregs in tumours. ....	226
5.2.8 Combined cancer immunotherapy using a breast cancer vaccine together with anti-CD25 MAb treatment increases survival of mice with breast cancer.....	231
5.2.9 Anti-CTLA-4 MAb therapy used either alone or in combination with breast cancer vaccination significantly increases tumour infiltrating CD8 <sup>+</sup> effector cells but does not affect levels of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> Tregs in tumours.....	235
5.2.10 Combining immunotherapy using a breast cancer vaccine together with anti-CTLA-4 MAb therapy significantly increases survival in mice with tumour burdens.....	239
<b>5.3 Discussion .....</b>	<b>243</b>

## **Chapter 6: Enhancing cancer immunotherapy using a galectin inhibitor combined with anti-CTLA-4 MAb therapy and a breast cancer vaccine 250**

### **6.1 Introduction ..... 251**

### **6.2 Results ..... 254**

6.2.1 Combining anti-CD25 MAb therapy with CTLA-4 blockade and anti-breast cancer vaccination does not further improve survival or tumour growth inhibition. 254

6.2.2 Combination therapy incorporating Gal-1 inhibition significantly increases the efficacy of an anti-cancer vaccine in the tumour burdened animals. .... 258

6.2.4 Treatment with breast cancer cell supernatants or recombinant Gal-1 protein promotes the conversion of CD4<sup>+</sup>CD25<sup>-</sup> naive T-cells to CD4<sup>+</sup>CD25<sup>+</sup>FoxP3<sup>+</sup> Tregs which can be prevented by TDG. .... 265

### **6.3 Discussion ..... 269**

## **Chapter 7: Concluding remarks ..... 276**

## **References ..... 296**

## **Appendix 1 ..... 317**

## List of figures

	Page
Figure 1.1	37
Figure 1.2	40
Figure 1.3	54
Figure 1.4	63
Figure 1.5	67
Figure 1.6	73
Figure 1.7	75
Figure 2.1	115
Figure 2.2	118
Figure 2.3	119
Figure 3.1	144
Figure 3.2	148
Figure 3.3	150
Figure 3.4	151
Figure 3.5	152
Figure 3.6	154
Figure 3.7	156
Figure 3.8	158
Figure 3.9	159

	breast cancer in the background population of the c-Neu transgenic mouse strain	
Figure 3.10	Statistical analysis of age of onset for spontaneously developing breast cancer in c-Neu transgenic mice treated with preventative vaccination with an anti-breast cancer vaccine	160
Figure 3.11	NeuTL Wild Type cells grow and progress into solid tumours in 100% of mice	163
Figure 3.12	Tumour growth and survival analysis of mice receiving prophylactic and treatment based vaccination regimens	166
Figure 3.13	Detection of <i>Fluc</i> <sup>+</sup> target cells by CCD camera imaging	171
Figure 3.14	Analysis of luciferase release from decreasing numbers of lysed cells	173
Figure 3.15	The effect of lysis buffer and tergitol on luciferase reporter activity	175
Figure 3.16	Effect of IFN treatment on the levels of luminescent signal produced by target cells	177
Figure 3.17	SYTOX <sup>®</sup> Green uptake profile of TritonX-100 treated dead and live viable NeuTL murine breast cancer cells	180
Figure 3.18	Analysis of the effect of vaccination on the cytolytic activity of lymphocytes isolated from vaccinated and non-vaccinated animals	181
Figure 4.1	Detection of Gal-1 expression by tumour cells	198
Figure 4.2	Detection and inhibition of rhGal-1 binding	198
Figure 4.3	Crystallographic structures of Gal-1 in complex with disaccharides	200
Figure 4.4	Detection and inhibition of rhGal-1 binding to whole MOLT-4 cells by solid phase ELISA	201
Figure 4.5	Addition of Gal-1 inhibiting disaccharides significantly increases MOLT-4 survival but has no effect on the growth of NeuTL breast cancer cells	202
Figure 4.6	Addition of galectin-blocking disaccharides enhances T-cell proliferation in splenic derived MLC prepared from vaccinated mice	203

Figure 4.7	The addition of rhGal-1 and galectin blocking TDG affects CD8, CD4 and CD25 subpopulations in MLC	204
Figure 4.8	Effect of addition of rhGal-1 and galectin blocking TDG on the cytolytic activity in splenic derived MLC's from vaccinated mice	204
Figure 4.9	Intratumoural injection of galectin blocking TDG alone or in combination with a whole syngeneic breast cancer cell vaccine significantly increases survival of tumour challenged mice	204
Figure 5.1	Tumour size is directly correlated with levels of CD25 <sup>+</sup> lymphocytes isolated from the tumour or spleens of tumour bearing mice	213
Figure 5.2	Levels of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> T-cells in lymphocyte populations from spontaneously derived versus induced/inoculated tumour burdened animals	215
Figure 5.3	Treatment with Treg inhibiting MAbs does not affect levels of CD8 <sup>+</sup> T-cells but significantly Treg populations	218
Figure 5.4	Treatment with anti-CD25 MAb significantly reduced CD25 <sup>+</sup> T-cell levels for prolonged periods of time whereas anti-CTLA-4 MAb does not	220
Figure 5.5	Combined treatment with vaccination using a whole syngeneic breast cancer vaccine together with anti-Treg MAbs increases the level of CD8 <sup>+</sup> populations in the spleen	223
Figure 5.6	Determining the optimal dose of anti-CD25 MAb for tumour growth inhibition	225
Figure 5.7	Combination therapy with a breast cancer vaccine together with anti-CD25 MAb promotes CD8 <sup>+</sup> TILs and reduced Tregs in tumours	228
Figure 5.8	Combination treatment with a whole cell breast cancer vaccine plus anti-CD25 MAb treatment significantly reduces tumour growth in mice with tumour burden	233
Figure 5.9	Anti-CTLA-4 MAb therapy used either alone or in combination with breast cancer vaccination significantly increases tumour infiltrating CD8 <sup>+</sup> effector cells but does not	236

	affect levels of CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> Tregs in tumours	
Figure 5.10	Combining immunotherapy with a breast cancer vaccine with anti-CTLA-4 MAb therapy significantly increases survival in mice with tumour burden	240
Figure 6.1	Efficacy of vaccine plus anti-CTLA4 MAb therapy is decreased by the additional inclusion of anti-CD25 MAb therapy	255
Figure 6.2	Triple combination immunotherapy with vaccine, anti-CTLA-4 and TDG most effectively inhibits tumour growth in mice with breast cancer	259
Figure 6.3	Combination immunotherapy increases the ratio of effector T-cells to T-regs in the treated breast cancers	262
Figure 6.4	Tumour cell conditioned supernatant and/or rhGal-1 protein mediate the conversion of CD4 <sup>+</sup> CD25 <sup>-</sup> naive T-cells to CD4 <sup>+</sup> CD25 <sup>+</sup> FoxP3 <sup>+</sup> Tregs	267
Appendix 1	Intratumoural injection of galectin blocking TDG alone or in combination with a whole syngeneic breast cancer cell vaccine significantly increases survival of tumour challenged mice.	316



## List of Tables

		Page
Table 1.1	A partial list of immunosuppressive factors selected to demonstrate their diversity and wide spectrum of effects on immune cells	42
Table 2.1	Tumour and hybridoma cell lines	90
Table 2.2	Reagents for cell culture, tumour implantation, and the preparation of vaccine and adjuvant therapies	91
Table 2.3	Equipment used for cell culture and vaccine preparation	92
Table 2.4	Antibodies and conjugates	93
Table 2.5	Reagents and equipment used for flow cytometry and cell sorting	94
Table 2.6	Primers and plasmids used in PCR reactions and DNA transfections	95
Table 2.7	Reagents used for molecular biological techniques including PCR, DNA amplification, purification and transfection	96
Table 2.8	Equipment used for DNA mini/maxi preparations, PCR and gel documentation	96
Table 2.9	Antibodies and Alexa dyes used for immunohistochemistry	97
Table 2.10	Reagents used for immunohistochemistry	97
Table 2.11	Equipment used for immunohistochemistry	98
Table 2.12	PCR master mix	104
Table 2.13	PCR cycling conditions	104
Table 2.14	The different interferon treatments tested with incubation	110

	time and their combinations on MHC class I expression	
Table 2.15	Definition of test samples analysed	125
Table 2.16	Definition of samples (DELFIa cytotoxicity assay)	127
Table 2.17	Definition of samples (Luciferase release assay)	129
Table 2.18	Alexa Fluor <sup>®</sup> extinction coefficients and correction factors	132
Table 3.1	Fold increase in Mean Fluorescence Intensity (MFI) of MHC class I antigen expression on the surface of NeuTL breast cancer cells treated over different time periods and with different IFNs.	144
Table 3.2	Schematic of treatment regimens to determine the effect of detergents on luciferase signal output	172
Table 4.1	Crystallographic summary of galectin-1 structures with bound TDG and LBA (values in parentheses are for the highest resolution shell)	197
Table 4.2	MLC's with combined rhGal-1/TDG show significantly greater CTL responses	203

## Abbreviations

2-ME	2-mercaptoethanol
Ag	Antigen
AICD	Activation induced cell death
Amax	Absorbance maximum
APC	Antigen presenting cell
APC-conjugated	Allophycocyanin-conjugated
APM	Antigen processing machinery
BATDA	bis (acetoxymethyl) 2,2':6',2"- terpyridine-6,6"- dicarboxylate
BCG	Bacille Calmette-Guerin
BCL-2	B-cell lymphoma protein-2
BRACA1/2	Breast cancer gene 1/2
BSA	Bovine serum albumin
CAM	Cellular adhesion molecule
cAMP	Cyclic adenosine monophosphate
CCD	Charge-coupled device
CML	Chronic myeloid leukaemia
CRD	Carbohydrate recognition domain
CSC	Cancer stem cell
CTL	Cytotoxic T-lymphocyte
CTLA-4	Cytotoxic T-lymphocyte antigen-4
DC	Dendritic cell
DFS	Disease free survival
DMEM	Dulbeccos's modified eagle medium
DMSO	Dimethyl sulfoxide
dNTP	Deoxynucleotide Triphosphate
DOL	Degree of labelling
DR-5	Death receptor-5
DSMB	Data safety monitoring board
EDTA	Ethylenediaminetetraacetic acid
EGFR	Epidermal Growth Factor Receptor

ELISA	Enzyme linked immunosorbant assay
Erk	Extracellular Signal-Regulated Kinase
E:T	Effector:Target
FACS	Fluorescent activated cell sorting
FCS	Foetal calf serum
FDA	Food and drug administration
FITC	Fluorescein isothiocyanate
FI	Fold increase
Gal-1	Galectin-1
GE	Gastroesophageal
GITR	Glucocorticoid-induced tumor necrosis factor receptor
GM-CSF	Granulocyte Macrophage Colony Stimulating Factor
HER-2	Human epidermal growth factor receptor 2
HNC	Head and neck cancer
IBD	Inflammatory bowel disease
IC50	Inhibitory concentration of 50%
ICAM	Intracellular adhesion molecule
IDO	Indolamine 2,3-dioxygenase
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
I.P.	Intra-peritoneal
I.T.	Intra-tumoural
I.V.	Intra-venous
LAK	Lymphokine-Activated Killer Cell
LN	Lymph node
MAb	Monoclonal antibody
MAPK	Mitogen-Activated Protein Kinases
MCP	Modified citrus pectin
MFI	Mean fluorescence intensity
MHC	Major histocompatibility class I/II

MLC	Mixed lymphocyte culture
MMP	Matrix metalloprotease
MMTV	Mouse Mammary Tumour Virus Long Terminal Repeat Promoter
mRNA	messenger ribonucleic acid
NBCS	New bourn calf serum
NKT	Natural killer T-cell
OTC	Optimal cutting temperature
OS	Overall survival
PBMC	Peripheral blood mononucleocyte
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
PD-1	Programmed cell death-1
pDC	Plasmacytoid dendritic cell
PE	Phycoerythrin
PI	Propidium iodide
PI3K	Phosphatidylinositol-3-Kinase
PTLD	Post Transplant Lymphoproliferative Disorder
rhGal-1	Recombinant human Galectin-1
rpm	Revolutions per minute
S.C.	Subcutaneous
SEM	Standard error of the mean
SPF	Specific pathogen free
TAA	Tumour associated antigen
TAP1/2	Transporter Associated with Antigen Processing ½
TCR	T-cell receptor
TDG	Thiodigalactoside
TGF-β	Transforming growth factor-beta
Th	T-helper cell
TIL	Tumour infiltrating lymphocyte
TNF	Tumour necrosis factor

TRAIL	Tumour necrosis factor-related apoptosis-inducing ligand
Treg	Regulatory T-cell
UV	Ultraviolet
Vb	Vinblastine
VEGF	Vascular Endothelial Growth Factor

## Acknowledgements

I would like to acknowledge first and foremost my supervisor Dr Steve Ralph, for giving me the opportunity to complete my studies in his laboratory, and for his supervision, guidance and support.

I express my sincere thanks to Pauline Low and Elwyn Gabutero for your encouragement, optimism and friendship. I would also like to thank my colleagues in the Ralph laboratory namely Sam Cutler, Ibtisam Ghazawi, Koichi Ito and Katie Powell for their help and support and for providing materials and protocols when needed.

I also wish to thank and acknowledge Danielle Jepson and Bevan Butcher for their participation in this research as part of their third year research project.

Thanks must also go to Ibtissam Abdul Jabba of the P.A. Hospital in Brisbane for her assistance with cell sorting and the Griffith University Animal Facility managers Simone Chmielewski and Anna Orthman for compiling invaluable detailed mouse records. I would also like to acknowledge Cameron Flegg for his assistance with imaging slides used in immunohistochemical experiments.

Heartfelt thanks to my family and friends for their unconditional love and support. Thank you to Mum, Dad, Adam, Ashlee and Aaron and all of my extended family for always being there whenever I needed it. Special thanks must go to Alana Cavill and David Hayllar for their undying confidence and faith in me. Finally I would like to thank my partner Elliott Nelson for his love and support throughout my candidature, without which this thesis would not be possible.

Finally I would like to dedicate my work to my father. I'm so sorry you never got to see the final finished product however I still feel you here and know you would be so proud.

